- Overview
- Key stats
- Stock price
- Financial performance
- Growth
- Valuations
- Efficiency
- Dividends
- Financial health
- Stocks
- Healthcare
- NASDAQ: PCRX
Price (delayed)
$26.46
Market cap
$1.22B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.15
Enterprise value
$1.59B
Pacira BioSciences, Inc.is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local ...
Highlights
Pacira BioSciences's gross profit has increased by 8% YoY and by 2.7% QoQ
The company's gross margin rose by 4.3% YoY
The company's quick ratio has shrunk by 51% YoY but it rose by 7% QoQ
The equity has declined by 11% year-on-year but it has increased by 3.8% since the previous quarter
The company's net income fell by 10% QoQ
Pacira BioSciences's EPS has decreased by 9% QoQ
Key stats
What are the main financial stats of PCRX
MarketValuationsEarnings
Shares outstanding
46.28M
Market cap
$1.22B
Enterprise value
$1.59B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.57
Price to sales (P/S)
1.75
EV/EBIT
N/A
EV/EBITDA
49.2
EV/Sales
2.26
Revenue
$700.97M
Gross profit
$530.54M
Operating income
-$73.37M
Net income
-$99.56M
EBIT
-$46.54M
EBITDA
$32.25M
Free cash flow
$178.75M
Per shareBalance sheetLiquidity
EPS
-$2.15
EPS diluted
-$2.15
Free cash flow per share
$3.87
Book value per share
$16.86
Revenue per share
$15.16
TBVPS
$24.38
Total assets
$1.55B
Total liabilities
$775.17M
Debt
$638.85M
Equity
$778.35M
Working capital
$435.21M
Debt to equity
0.82
Current ratio
2.4
Quick ratio
1.93
Net debt/EBITDA
11.23
MarginsEfficiencyDividend
EBITDA margin
4.6%
Gross margin
75.7%
Net margin
-14.2%
Operating margin
-10.5%
Return on assets
-6.3%
Return on equity
-12.1%
Return on invested capital
-3.8%
Return on capital employed
-3.7%
Return on sales
-6.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PCRX stock price
How has the Pacira BioSciences stock price performed over time
Intraday
-1.08%
1 week
2.88%
1 month
6.31%
1 year
-3.15%
YTD
40.45%
QTD
6.48%
Financial performance
How have Pacira BioSciences's revenue and profit performed over time
Revenue
$700.97M
Gross profit
$530.54M
Operating income
-$73.37M
Net income
-$99.56M
Gross margin
75.7%
Net margin
-14.2%
PCRX financials
The company's operating income has shrunk by 184% YoY and by 13% QoQ
PCRX's operating margin has shrunk by 181% YoY and by 13% QoQ
The company's net income fell by 10% QoQ
Pacira BioSciences's gross profit has increased by 8% YoY and by 2.7% QoQ
Price vs fundamentals
Earnings waterfall
Growth
What is Pacira BioSciences's growth rate over time
PCRX growth chart
Valuation
What is Pacira BioSciences stock price valuation
P/E
N/A
P/B
1.57
P/S
1.75
EV/EBIT
N/A
EV/EBITDA
49.2
EV/Sales
2.26
Valuation vs average
Price to earnings (P/E)
Pacira BioSciences's EPS has decreased by 9% QoQ
Price to book (P/B)
PCRX's P/B is 47% below its 5-year quarterly average of 3.0 but 22% above its last 4 quarters average of 1.3
The equity has declined by 11% year-on-year but it has increased by 3.8% since the previous quarter
Price to sales (P/S)
The price to sales (P/S) is 54% lower than the 5-year quarterly average of 3.8 but 17% higher than the last 4 quarters average of 1.5
The revenue has grown by 3.9% YoY
Efficiency
How efficient is Pacira BioSciences business performance
Pacira BioSciences's ROIC has plunged by 159% YoY and by 19% from the previous quarter
Pacira BioSciences's return on sales has shrunk by 155% YoY and by 16% QoQ
PCRX's ROE is down by 13% since the previous quarter
Pacira BioSciences's ROA has decreased by 11% from the previous quarter
Dividends
What is PCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PCRX.
Financial health
How did Pacira BioSciences financials performed over time
Assets vs liabilities
The total assets is 100% greater than the total liabilities
The current ratio has plunged by 54% YoY but it has grown by 7% from the previous quarter
The company's quick ratio has shrunk by 51% YoY but it rose by 7% QoQ
Debt vs equity
Pacira BioSciences's debt is 18% less than its equity
Pacira BioSciences's debt to equity has increased by 22% YoY but it has decreased by 4.7% from the previous quarter
The equity has declined by 11% year-on-year but it has increased by 3.8% since the previous quarter
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.